| HS Code | 468057 |
| Product Name | Wumei Powder Veterinary Grade API |
| Active Ingredient | Wumei (Fructus Mume) Extract |
| Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Appearance | Brownish to yellowish-brown powder |
| Odor | Characteristic aromatic odor |
| Solubility | Sparingly soluble in water, soluble in dilute ethanol |
| Particle Size | 95% passes through 80 mesh |
| Storage And Shelf Life | Store in a cool, dry, airtight container; 24 months |
As an accredited Wumei Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaging: 25 kg per fiber drum, double polyethylene-lined, moisture-proof sealed, with clear label for veterinary use and API grade. |
| Container Loading (20′ FCL) | 20′ FCL container loaded with Wumei veterinary-grade powder API in sealed drums, suitable for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Shipping | Wumei Powder Veterinary Grade API ships in sealed, moisture-proof drums with tamper-evident packaging, compliant with international transport regulations. We offer expedited air and sea freight, temperature-controlled options, and full documentation including SDS and certificate of analysis to ensure safe, traceable delivery worldwide. |
| Storage | Store in a cool, dry, well-ventilated area away from direct sunlight, moisture, and heat. Keep the container tightly sealed when not in use. Protect from incompatible substances and avoid exposure to high humidity. Use appropriate personal protective equipment when handling. Follow local regulations for safe storage and disposal. |
| Shelf Life | Shelf life is typically 24 months from manufacture date when stored tightly sealed in a cool, dry place. |
In poultry operations where nipple drinker lines operate at 2.0–3.5 bar and water hardness exceeds 300 mg/L CaCO₃, Wumei powder (Fructus Mume) is converted into a water-dispersible powder rather than a simple milled herb because residual plant fibres above 200 µm obstruct pressure regulators and nipple valves. The manufacturing record for this dosage form requires the API to pass a 150 µm sieve with ≥95% recovery and a loss-on-drying specification of ≤8.0% w/w before weighing. A typical veterinary-grade batch is dry-blended with dextrose monohydrate and sodium chloride in a double-cone blender at 20 rpm for 25–35 min; the sequence is staged so that the API is pre-mixed with an equal mass of carrier for 10 min before the remaining carrier is added, preventing segregation caused by density differences between the fibrous API and crystalline carrier.
Industry compliance standards: batch release follows the microbial limits of Ph. Eur. 5.1.4 for non-sterile veterinary preparations, with Salmonella absent in 25 g, Escherichia coli ≤10 CFU/g, and total aerobic microbial count ≤10⁴ CFU/g. Residual solvent testing is performed under VICH GL18 where the API is dried with ethanol-water mixtures; if aqueous extraction only is used, the applicant must provide a declaration and chromatographic absence of ethanol above 0.5% w/w. Finished water-soluble powder is authorized as a veterinary medicinal product under EU Regulation 2019/6 where marketed in the EEA, while US-bound formulations are manufactured under 21 CFR 211.110 for in-process control.
Formulation addition ratio: the field dose is 1.0–2.0 g Wumei powder per litre of drinking water for 5–7 days; the packaged soluble powder is typically diluted at 10–20 g finished powder per 100 L water, equivalent to 0.01–0.02% w/v finished product concentration.
Downstream production process: after blending, the powder is filled into aluminium-foil sachets or HDPE jars with desiccant; fill weight is controlled to ±2% relative deviation on a 10-head auger filler. Terminal product types: 100 g, 500 g, 1 kg sachets and 25 kg bulk cartons for farm use. At relative humidity above 60%, the API must be pre-dried at 50–60°C in a vacuum tray dryer for 4–6 h because organic acid components absorb moisture and reduce flowability below the auger filler’s 0.8 g/s threshold.
Feed mills adding Wumei powder to piglet creep feed encounter flow stagnation in ribbon mixers when the carrier moisture rises above 12% w/w, because the API’s water-soluble organic acid fraction forms a cohesive film on steel blades and reduces the 15-minute blend uniformity below a relative standard deviation of 5%. The critical control point is not the API concentration but the water activity of the premix carrier; when ground rice hulls or corncob grits are used, pre-conditioning at 60°C for 20 min lowers water activity to 0.35–0.45 before Wumei powder is introduced.
Industry compliance standards: for medicated feed in the US, this line operates under 21 CFR 225 current good manufacturing practice for medicated feeds; for the EU market, the intermediate premix is subject to Good Manufacturing Practice under EU Regulation 2019/6 and the feed hygiene framework of Regulation (EC) No 183/2005. Premix uniformity is verified by tracer salt recovery using a 200 g/kg sodium chloride tracer and salt titre method consistent with ISO 6497.
Formulation addition ratio: a 10% w/w medicated premix contains 100 kg Wumei powder, 895 kg ground rice hulls, and 5 kg silicon dioxide per 1000 kg. In final complete feed, the inclusion is 2.0–3.0 kg API per tonne for post-weaning piglets; broiler finisher feeds are limited to 1.0–2.0 kg per tonne because higher levels depress feed intake through sour taste.
| Premix type | Wumei powder | Carrier | Silicon dioxide | Mixing time | Final feed inclusion |
| 10% w/w | 100 g/kg | 895 g/kg rice hulls | 5 g/kg | 20 min | 20 kg premix/tonne, delivering 2 kg API/tonne |
| 5% w/w | 50 g/kg | 945 g/kg corncob meal | 5 g/kg | 15 min | 40 kg premix/tonne, delivering 2 kg API/tonne |
Downstream production process: Wumei powder is pre-mixed with 10% of the carrier in a 200-litre paddle mixer for 5 min; the blend is then discharged into a 1,000-litre ribbon mixer and mixed for 15–20 min at 35 rpm. Batch records record mixer amperage, blend uniformity by tracer salt recovery, and post-mix particle segregation. Terminal product types: 25 kg multi-wall paper bags with a 0.5 mm LDPE liner, shipped as 10% w/w and 5% w/w medicated premixes for licensed feed mills.
Granulation of Wumei powder for tablet compression begins with moisture-sensitive binder selection because the API’s organic acid fraction depresses plastic deformation of microcrystalline cellulose and produces edge chipping when compaction pressure exceeds 120 MPa. Direct compression is feasible only at API loads ≤30% w/w; above this threshold, tablet hardness drops below 40 N and friability exceeds 1% due to poor particle interlocking of the lignified plant fibre. A robust high-dose formula replaces direct compression with wet granulation using a 10% w/w aqueous povidone K30 solution sprayed at 8–12 g/min onto the API-lactose mixture in a high-shear granulator; granule growth is terminated at 1.0–1.5 mm median particle size and 5–7% w/w moisture.
Industry compliance standards: finished tablets comply with USP <905> for content uniformity, USP <1216> for tablet friability, and USP <711> dissolution if a dissolution test is required by the target market. Botanical raw material quality is assessed under USP <561> for botanical articles, and elemental impurity risk is addressed by ICH Q3D. Manufacturing is performed under 21 CFR 211 for finished pharmaceuticals.
Formulation addition ratio: a 250 mg Wumei tablet contains 40–60% w/w API, 30–45% w/w microcrystalline cellulose PH-102, 2–5% w/w crospovidone, 0.5–1.0% w/w magnesium stearate, and 0.5–1.5% w/w colloidal silicon dioxide. Capsule fill formulations use 300 mg Wumei powder per size 0 capsule with 30% w/w lactose monohydrate and 2% w/w sodium starch glycolate.
Downstream production process: wet granules are dried in a fluid bed dryer at inlet air temperature 60–65°C and product temperature 40–45°C to final moisture 5–7% w/w; the dried granules are milled through a 1.0 mm conical screen and lubricated for 2 min. Tablets are compressed on a rotary press at 8–14 kN target force, hardness 50–70 N, and friability ≤1.0% w/w; capsules are filled on an intermittent-motion capsule machine with a 10–15% weight variation limit. Terminal product types: 100 mg and 250 mg tablets; size 0 and size 1 capsules packed in aluminium-PVC/PE/PVDC blister or HDPE bottles with silica gel.
Oral granules containing Wumei powder are formulated as a dispersed powder mixed with electrolyte salts and sweeteners; the main process conflict is the API’s acid release into the granulation fluid, which accelerates sucrose inversion and creates sticky agglomerates when the product temperature exceeds 45°C during fluid bed drying. Granulation is therefore run with a 20–30% w/w purified water load and a short 3–5 min high-shear mixing phase before drying, preventing free water accumulation that would dissolve the sucrose fraction and bind the batch into a non-dischargeable mass.
Industry compliance standards: oral granules for food-producing species follow EU Regulation 2019/6 for veterinary medicinal products; if the granule is marketed as a complementary feed material, the line operates under ISO 22000:2018 clause 8.2 and HACCP principles. Heavy metal limits are assessed by ICH Q3D; microbial quality by Ph. Eur. 5.1.4; and loss on drying by Ph. Eur. 2.2.32.
Formulation addition ratio: Wumei powder 5.0–10.0% w/w, lactose monohydrate 65.0–75.0% w/w, sucrose 10.0–15.0% w/w, povidone K30 2.0–4.0% w/w, sodium chloride 0.5–1.5% w/w, potassium chloride 0.5–1.0% w/w, citric acid 0.3–0.8% w/w, flavour 0.2–0.5% w/w. The granulation liquid is purified water at 20–30% of dry powder mass.
Downstream production process: fluid bed top-spray granulation at inlet air temperature 70–75°C, product temperature 35–40°C, spray rate 8–15 g/min; the granules are dried to ≤5% w/w moisture, then sieved to retain 150–850 µm. Terminal product types: 10% w/w oral granules packed in 50 g, 100 g, 500 g aluminium pouches or 1 kg jars; the product is mixed with milk replacer or oral rehydration solution at 2.0–5.0 g per litre.
Aqueous oral solutions containing dispersed Wumei powder require pH control at 4.0–4.5 because the raw API releases citric and malic acids into solution and drifts below pH 3.2 within 30 minutes when unbuffered, destabilizing xanthan gum and producing sedimentation greater than 10% v/v in 24 h. Suspension stability is maintained with a structured vehicle rather than a simple syrup; xanthan gum at 0.2–0.5% w/v provides a yield stress of 0.3–0.8 Pa at 25°C, sufficient to keep particles with median size 75–150 µm suspended under accelerated storage at 40°C/75% RH for 6 months.
Industry compliance standards: the oral solution is a non-sterile veterinary medicinal product under EU Regulation 2019/6; preservative efficacy is tested according to Ph. Eur. 5.1.3, microbial limits according to Ph. Eur. 5.1.4, and packaging leachables under ICH Q3D. If the product is marketed in the US, 21 CFR 211 applies to the manufacturer, but the product is not subject to USP <788> because it is not a parenteral preparation.
Formulation addition ratio: Wumei powder 5.0–10.0% w/v, xanthan gum 0.2–0.5% w/v, sodium benzoate 0.1–0.2% w/v, potassium sorbate 0.05–0.1% w/v, citric acid monohydrate 0.1–0.3% w/v, sodium citrate dihydrate 0.05–0.15% w/v, sodium cyclamate 0.05–0.1% w/v, purified water q.s. to 100 mL. The API is used as a suspension, not a true solution, because water-insoluble plant fibre remains after 25°C reconstitution.
Downstream production process: high-shear dispersion at 6,000–10,000 rpm for 15–20 min hydrates the gum; the API is then added under vacuum to avoid foaming, followed by pH adjustment with citric acid/sodium citrate buffer to 4.0–4.5. The batch is deaerated at -0.08 MPa for 10 min before filling into HDPE bottles with child-resistant dosing syringes. Terminal product types: 100 mL, 250 mL, 500 mL oral suspension bottles and 5 L livestock dispensing packs. The crude powder formulation is not suitable for injection; parenteral use would require a purified, depyrogenated extract with bacterial endotoxin below 0.5 EU/mg and particulate matter controlled per USP <788>.
At API loads of 45% w/w and above, direct compression with microcrystalline cellulose PH-102 shows a nonlinear loss of tensile strength; a 45% w/w Wumei batch compressed at 8 kN yields hardness 35–40 N and friability 1.0–1.5% w/w, while the same formulation at 60% w/w yields hardness 22–28 N and friability 2.0–2.5% w/w, with visible lamination at the tablet edge. The defect mechanism is not purely elastic recovery; the organic acid fraction of the API plasticizes the amorphous regions of crospovidone and reduces interparticle bond strength, especially when moisture exceeds 6% w/w.
| API load | Process route | Compression force | Mean hardness | Friability | Ejection force | Observed defect |
| 30% w/w | Direct compression | 8 kN | 65 N | 0.4% | 180 N | None |
| 45% w/w | Direct compression | 8 kN | 38 N | 1.2% | 220 N | Edge chipping |
| 60% w/w | Direct compression | 8 kN | 25 N | 2.4% | 260 N | Lamination |
| 60% w/w | Wet granulation | 12 kN | 75 N | 0.3% | 200 N | None |
Industry compliance standards: this development work is performed under 21 CFR 211.65 for equipment validation and 21 CFR 211.100 for written production and process control; friability testing is per USP <1216>, hardness by a motorized hardness tester with 0.1 N resolution, and dissolution screening per USP <711>. Residual moisture is determined by Ph. Eur. 2.2.32.
Formulation addition ratio: direct compression batches are 30–60% w/w Wumei powder, 35–60% w/w microcrystalline cellulose PH-102, 3% w/w crospovidone, 1% w/w colloidal silicon dioxide, 0.75% w/w magnesium stearate. The wet-granulated alternative uses 60% w/w Wumei powder, 31% w/w lactose monohydrate, 5% w/w povidone K30, 3% w/w crospovidone, 1% w/w magnesium stearate.
Downstream production process: for direct compression, all ingredients are sieved through an 800 µm screen, blended in a bin blender at 12 rpm for 20 min, and compressed on a 27-station rotary press with 9.5 mm round tooling at 8 kN. For wet granulation, API, lactose, and crospovidone are granulated with a 10% w/w aqueous povidone K30 solution in a high-shear mixer at impeller 300 rpm and chopper 1,500 rpm for 3–5 min; granules are dried to 4–6% w/w moisture and compressed at 12 kN. Terminal product types: high-dose 500 mg tablets for swine and bovine oral administration, packed in 100-tablet HDPE jars or aluminium blisters.
Competitive Wumei Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Wumei Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a multi-route active pharmaceutical ingredient powder supplied for further processing into solid, semi-solid, and liquid veterinary dosage forms. The material is released against pharmacopoeial and Veterinary International Conference on Harmonisation guidelines applicable to veterinary APIs, with control of assay, related substances, residual solvents, heavy metals, loss on drying, and particle size distribution. In tableting and capsule filling, flowability and bulk density are critical because low-dose formulations containing 5.0 mg active per unit require extensive dilution with excipients; blend segregation at this scale is a routine failure mode observed on production-scale container blenders and ribbon blenders. The powder grade is differentiated from technical-grade raw material by lower levels of unspecified impurities, residual solvent control under USP <467> and Ph. Eur. 5.4, and a particle size range adapted to dry blending, wet granulation, roller compaction, and sterile reconstitution. The full product name identifies the grade; a separate model number is not standardized in the available technical literature. Published data for the specific Wumei batch performance under high-speed rotary compression is limited; therefore, blending and compression parameters must be validated on the actual formulation.
Preformulation tests for pH-dependent solubility, intrinsic dissolution rate, and solid-state stability determine which of the listed routes are viable. For oral solution, solubility must be measured in purified water and buffered media at 25 °C and 37 °C; if the API remains below 20 mg/mL, co-solvents such as propylene glycol or glycofurol may be needed. For tablets and capsules, hygroscopicity above 2.0% weight gain at 75% RH indicates that protective packaging and wet granulation may be required. The powder's acceptance for injections depends on endotoxin control and compatibility with terminal sterilization or sterile filtration; published data for this specific configuration is limited.
For a veterinary API intended for multiple finished dosage forms, the release specification commonly includes assay on the dried basis of 98.0% to 102.0% w/w, total unspecified individual impurities no more than 0.5% w/w, and total related substances no more than 1.0% w/w. Compendial identification is confirmed by infrared absorption spectrophotometry and high-performance liquid chromatography retention time. Loss on drying is generally controlled at ≤ 1.0% w/w, and residue on ignition at ≤ 0.1% w/w. Because the powder is intended for non-sterile solid and premix manufacture, microbial limits align with VICH GL18 and the relevant USP general chapter, with total aerobic microbial count ≤ 10³ CFU/g, total combined yeasts and moulds ≤ 10² CFU/g, and absence of Salmonella and Escherichia coli. For injectable applications, the finished solution or lyophilisate must meet USP <85> bacterial endotoxin limits; the bulk API itself is not automatically sterile and must be sterilized or filtered during manufacture.
Particle size is controlled by air-jet milling for fine grade and by sieving for coarse grade. Laser diffraction with ISO 9276-2 reporting of d10, d50, and d90 is preferred over sieve analysis for fine powders because sieve meshes below 75 μm are prone to agglomeration errors. Bulk density and tapped density are determined according to USP <616>; a Hausner ratio above 1.35 indicates poor flow and may require granulation or addition of glidant. The powder's flowability directly affects tablet weight uniformity on high-speed presses; a free-flowing material with Carr index below 20% is generally acceptable for direct compression.
The same bulk powder may not satisfy direct compression and sterile reconstitution without engineering of particle size and surface properties. For direct compression, powders with d50 between 25 μm and 45 μm and d90 ≤ 80 μm are often compatible with direct compression using microcrystalline cellulose and lactose monohydrate, but segregation occurs when the API particle size differs from the excipient by more than 3-fold. High-shear wet granulation with a hydroxypropyl methylcellulose binder solution at 3.0% w/w can yield granules with d50 between 150 μm and 400 μm, reducing segregation in low-dose premixes. On a production rotary tablet press operating at 60–100 rpm, die fill weight variability is governed by powder bulk density; a batch-to-batch change greater than 0.10 g/mL has been observed to shift tablet weight relative standard deviation above 2.0% in direct compression. In aseptic filling of injectables, the API is generally dissolved and sterilized by filtration through a 0.22 μm polyvinylidene fluoride membrane; the powder itself is not considered sterile unless a validated terminal sterilization or sterile crystallization process is used.
| Formulation route | Particle size target | Typical production equipment | Critical control point |
|---|---|---|---|
| Tablets / capsules | d50 10–45 μm, d90 ≤ 80 μm | 27-station rotary press or dosator capsule filler | Blend uniformity RSD ≤ 5.0% per USP <905> |
| Powders / granules / premix | d50 80–250 μm, carrier-matched crystals | Ribbon blender or twin-screw mixer | Homogeneity at 1:100 dilution by HPLC or UV |
| Injections / solutions | particle size not critical; dissolution rate and purity control | Jacketed stainless steel compounding tank, 0.22 μm membrane filter | Endotoxin and particulate matter per USP <85> and USP <788> |
Dry granulation by roller compaction is preferred when the API shows moisture sensitivity or poor flow under direct compression. A production-scale roller compactor with roll diameter 120–250 mm and roll gap 1–3 mm can produce ribbons with density 1.0–1.3 g/cm³; milling through an oscillating granulator fitted with 0.8–1.5 mm screen yields granules with friability below 2.0%. Colloidal silicon dioxide at 0.5–1.0% w/w and croscarmellose sodium at 1.0–5.0% w/w are standard flow and disintegrant additions. Batch-to-batch variance in granule particle size after milling is controlled by sieve analysis using 850 μm and 150 μm screens; oversize above 20% indicates roll pressure drift or screen wear. For medicated premix operations, the API is first triturated with a suitable carrier such as corn starch or calcium carbonate to a 1:10 intermediate dilution before addition to the main batch; this reduces active carryover risk in the mixer discharge chute.
Formulation development for capsules often employs dry powder filling with a dosator nozzle because it is less sensitive to API flow, but fill weight can vary when bulk density is below 0.40 g/mL. In capsule filling, the use of hydrophobic lubricants such as magnesium stearate above 1.5% w/w can delay dissolution in low-dose formulations; blending time should be limited to 3–5 min after lubricant addition to avoid over-lubrication. For premix and granule combinations, a twin-screw mixer with L/D ratio 20:1 to 40:1 can disperse the API uniformly at concentrations as low as 0.1% w/w, but the feed rate must be matched to screw speed to prevent powder buildup in the barrel.
Residual solvent limits are tighter when the same API powder is destined for injectable or oral solution manufacturing because the solvent is not removed by tableting excipients and may exert direct toxicological effects. Under VICH GL18, class 1 solvents such as benzene and carbon tetrachloride must be absent or below the concentration limits in USP <467> Option 2. Class 2 solvents are controlled with typical acceptance values of methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm, toluene ≤ 890 ppm, and N,N-dimethylformamide ≤ 880 ppm; class 3 solvents are limited to 5000 ppm or justified by good manufacturing practice. For sterile injection, the final solution must meet USP <85> bacterial endotoxin limit for the product-specific dose; the bulk API may require pre-treatment with activated carbon or ultrafiltration if endotoxin levels exceed the calculated limit. Dissolution rate and pH stability also differ: an API that dissolves completely in a non-aqueous co-solvent may precipitate upon dilution with 0.9% w/v sodium chloride intravenous carrier, forming particles larger than 25 μm that are detectable under USP <788> light obscuration particle count.
For injectable preparation, the solution is often filtered through two 0.22 μm sterilizing-grade filters in series; pre-filter pressure above 0.5 bar during holding may indicate aggregation or microbial load. The final solution holding time before filling should not exceed 24 h at 2–8 °C unless stability data supports longer. The powder is particulate and non-sterile as supplied; sterile injection manufacturing therefore places the entire burden of sterility, depyrogenation, and particulate control on the downstream compounding line.
Finished tablets prepared from the powder are tested for dissolution using USP <711> Apparatus 2 with paddle speed 50 rpm in 900 mL of buffered media at 37 °C. An immediate-release veterinary tablet should typically release not less than 80% of label claim within 30 min in pH 6.8 buffer, but actual product-specific specifications depend on the approved target animal bioavailability. In laboratory trials, batches with granule d50 outside 150–350 μm showed slower dissolution at 30 min; this is a known scale-up risk when moving from high-shear granulator to production twin-screw granulation.
The powder must be stored in sealed polyethylene-lined aluminum foil bags with desiccant because moisture uptake above 2.0% w/w can reduce flowability and initiate hydrolysis. Long-term stability storage under 25 °C / 60% RH and accelerated conditions 40 °C / 75% RH is used to assign retest periods. In multi-active premixes, avoid dry blending with strongly alkaline carriers such as sodium carbonate or amine-based additives unless compatibility has been demonstrated, because acid-sensitive APIs can undergo salt disproportionation and liberate free base with reduced dissolution. Formulation with reducing sugars in chewable tablets may generate Maillard degradation products under accelerated conditions; published data for this specific API configuration is limited. For oral solutions, pH is typically adjusted to 4.5–6.5 with citrate or phosphate buffer to maintain chemical stability and palatability.
The veterinary grade is distinguished from technical powder by controlled related substances, residual solvents, and microbial limits. Technical powder may contain total impurities above 2.0% and may carry process-related catalysts or ligands that are unacceptable in parenteral use. Human API often includes additional genotoxic impurity controls and a full ICH M7 risk assessment, while veterinary APIs follow VICH GL11 and VICH GL18 but may have route-specific allowances for non-food-producing species. The following matrix summarizes the differentiation.
| Release parameter | Wumei Powder Veterinary Grade API | Technical powder | Human-grade API reference |
|---|---|---|---|
| Related substances | unspecified individual ≤ 0.5%, total ≤ 1.0% | often not reported or > 2.0% | per monograph; threshold may be below 0.10% for high-dose APIs |
| Residual solvents | VICH GL18 / USP <467> | not controlled | ICH Q3C / USP <467> |
| Microbial limits | TAMC ≤ 10³ CFU/g, TYMC ≤ 10² CFU/g | variable or unsuitable | same for non-sterile; stricter for injection |
| Endotoxin | controlled only if injection use | not applicable | controlled for parenteral use |
| Particle size | route-specific d50 10–250 μm | broad variable | route-specific |
| Documentation | Certificate of Analysis, TSE/BSE statement, residual solvent declaration | limited | full regulatory dossier with genotoxic impurity assessment |
Packaging configuration for the veterinary powder typically includes 25 kg net weight in food-grade low-density polyethylene liners inside corrugated fiber drums or aluminium foil bags under nitrogen. The container closure system must prevent moisture ingress: desiccant sachets containing silica gel or molecular sieves are placed in the headspace. Shipment under uncontrolled tropical conditions can raise moisture content above 1.0% within 72 h if the foil seal is damaged; therefore, incoming inspection should include loss on drying by Karl Fischer or thermogravimetric analysis before use. The retest period is set from long-term stability data, but storage above 30 °C or 75% RH can shorten it. For sterile injectable manufacturing, the drug substance is often subdivided in a grade D or grade C cleanroom before transfer to the aseptic filling line to avoid microbial contamination.
